Medtronic plc (MDT) Hisse Analizi
Yalnızca bilgilendirme amaçlıdır. Finansal tavsiye değildir. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
87.14$'dan işlem gören Medtronic plc (MDT), 112B değerindeki bir Healthcare şirketidir. Hisse senedi, 9 kantitatif KPI'ya dayalı olarak orta dereceli bir derecelendirme olan 56/100 puan alıyor.
Son analiz: 8 Şub 2026Medtronic plc (MDT) Sağlık ve Boru Hattı Genel Bakışı
Medtronic, a global leader in medical technology, offers diverse device-based therapies across cardiovascular, medical-surgical, neuroscience, and diabetes sectors, driving growth through innovation, strategic acquisitions, and expanding global reach, with a current dividend yield of 2.75% and a profit margin of 13.7%.
Yatırım Tezi
Medtronic presents a notable research candidate due to its diversified portfolio of medical devices, consistent profitability, and commitment to innovation. With a market capitalization of $131.98 billion and a P/E ratio of 27.68, Medtronic demonstrates financial stability and growth potential. The company's 13.7% profit margin and 62.3% gross margin highlight its operational efficiency. Key growth catalysts include the increasing adoption of minimally invasive surgical techniques, the growing prevalence of chronic diseases like diabetes and cardiovascular disorders, and the expansion of its robotic-assisted surgery platform. Furthermore, Medtronic's dividend yield of 2.75% provides a steady income stream for investors. The company's strong market position and ongoing investments in research and development position it for long-term success.
FMP finansallarına ve nicel analizine dayanmaktadır
Temel Önemli Noktalar
- Market capitalization of $131.98 billion, reflecting its strong market position in the medical device industry.
- P/E ratio of 27.68, indicating investor confidence in its earnings potential.
- Profit margin of 13.7%, demonstrating efficient operations and profitability.
- Gross margin of 62.3%, showcasing its ability to maintain competitive pricing and manage costs effectively.
- Dividend yield of 2.75%, providing a steady income stream for investors.
Rakipler & Benzerleri
Güçlü Yönler
- Diversified product portfolio across multiple therapeutic areas.
- Strong global presence and distribution network.
- Commitment to innovation and research and development.
- Established relationships with healthcare providers and key opinion leaders.
Zayıflıklar
- Exposure to regulatory risks and product liability claims.
- Dependence on third-party suppliers for certain components and materials.
- Intense competition in the medical device industry.
- Potential for product recalls and safety concerns.
Katalizörler
- Upcoming: Regulatory approvals for new products and therapies in key markets.
- Ongoing: Increasing adoption of minimally invasive surgical techniques.
- Ongoing: Growing prevalence of chronic diseases like diabetes and cardiovascular disorders.
- Ongoing: Expansion of robotic-assisted surgery platform.
Riskler
- Potential: Product liability claims and recalls.
- Potential: Regulatory delays and unfavorable reimbursement policies.
- Ongoing: Intense competition from other medical device companies.
- Ongoing: Economic downturns and reduced healthcare spending.
- Potential: Disruptive technologies rendering existing products obsolete.
Büyüme Fırsatları
- Expansion of Robotic-Assisted Surgery Platform: Medtronic's Hugo robotic-assisted surgery system represents a significant growth opportunity. The global surgical robotics market is projected to reach $12.6 billion by 2025. By expanding the applications of the Hugo system and gaining regulatory approvals in key markets, Medtronic can capture a larger share of this rapidly growing market. The timeline for significant revenue contribution is expected within the next 3-5 years.
- Diabetes Management Innovation: The increasing prevalence of diabetes globally drives the demand for advanced diabetes management solutions. Medtronic's continuous glucose monitoring (CGM) systems and smart insulin pen systems offer significant growth potential. The global diabetes care devices market is expected to reach $30 billion by 2027. Medtronic can capitalize on this trend by developing more accurate and user-friendly CGM devices and integrating them with insulin delivery systems.
- Cardiovascular Device Advancements: Medtronic's Cardiovascular Portfolio benefits from continuous advancements in cardiac rhythm management, heart valve technologies, and vascular therapies. The global cardiovascular device market is projected to reach $60 billion by 2028. By introducing innovative products like leadless pacemakers and transcatheter valve replacement systems, Medtronic can maintain its leadership position and drive revenue growth.
- Neuroscience Portfolio Expansion: Medtronic's Neuroscience Portfolio offers opportunities in spinal surgery, neurosurgery, and pain management. The global neurotechnology market is expected to reach $16.5 billion by 2027. By expanding its product offerings in areas like neuromodulation and neurovascular therapies, and through robotic guidance systems, Medtronic can address a broader range of neurological disorders and drive growth.
- Emerging Markets Penetration: Expanding its presence in emerging markets like China, India, and Brazil presents a significant growth opportunity for Medtronic. These markets are experiencing rapid economic growth and increasing healthcare spending. By tailoring its products and services to meet the specific needs of these markets and establishing strategic partnerships with local healthcare providers, Medtronic can tap into a large and growing patient base.
Fırsatlar
- Expanding into emerging markets with high growth potential.
- Developing new and innovative medical devices and therapies.
- Acquiring complementary businesses and technologies.
- Leveraging digital health technologies to improve patient outcomes.
Tehditler
- Increasing pricing pressure from healthcare payers.
- Changes in healthcare regulations and reimbursement policies.
- Technological disruptions and the emergence of new competitors.
- Economic downturns and reduced healthcare spending.
Rekabet Avantajları
- Strong brand reputation and established relationships with healthcare providers.
- Extensive patent portfolio protecting its innovative technologies.
- Global distribution network and established presence in key markets.
- High switching costs for customers due to the complexity and reliability of medical devices.
MDT Hakkında
Founded in 1949, Medtronic has evolved from a small medical equipment repair shop into a multinational medical technology giant. The company develops, manufactures, and sells a wide range of device-based medical therapies, addressing various healthcare needs across the globe. Medtronic operates through four main segments: the Cardiovascular Portfolio, which includes implantable pacemakers, defibrillators, and related cardiac therapies; the Medical Surgical Portfolio, offering surgical stapling devices, vessel sealing instruments, and robotic-assisted surgery products; the Neuroscience Portfolio, providing products for spinal surgeons, neurosurgeons, and pain management specialists; and the Diabetes Operating Unit, which focuses on insulin pumps, continuous glucose monitoring systems, and related diabetes management technologies. Headquartered in Dublin, Ireland, Medtronic serves healthcare systems, physicians, clinicians, and patients in over 150 countries. The company's commitment to innovation and strategic acquisitions has solidified its position as a market leader, with a strong emphasis on improving patient outcomes and transforming healthcare delivery.
Ne Yaparlar
- Develops and manufactures implantable cardiac pacemakers and defibrillators.
- Produces surgical stapling devices and vessel sealing instruments.
- Offers continuous glucose monitoring systems and insulin pumps for diabetes management.
- Provides products for spinal surgeons and neurosurgeons.
- Manufactures aortic valves and surgical valve replacement products.
- Offers robotic-assisted surgery systems.
- Provides therapies for vasculature in and around the brain.
İş Modeli
- Develops and manufactures a wide range of medical devices and therapies.
- Sells products directly to healthcare systems, physicians, and clinicians.
- Generates revenue through product sales, service contracts, and licensing agreements.
- Invests heavily in research and development to drive innovation and new product development.
Sektör Bağlamı
Medtronic operates in the dynamic medical device industry, characterized by continuous innovation and increasing demand for advanced healthcare solutions. The global medical device market is projected to reach trillions of dollars by 2026, driven by an aging population, rising prevalence of chronic diseases, and technological advancements. Medtronic competes with companies like Boston Scientific (BSX), Bristol-Myers Squibb (BMY), CVS Health (CVS), Edwards Lifesciences (EW), and GSK plc (GSK). Medtronic's broad product portfolio, global presence, and commitment to innovation position it favorably in this competitive landscape.
Kilit Müşteriler
- Hospitals and healthcare systems
- Physicians and surgeons
- Clinics and outpatient centers
- Patients with chronic medical conditions
Finansallar
Grafik & Bilgi
Medtronic plc (MDT) hisse senedi fiyatı: $87.14 (-0.53, -0.60%)
Son Haberler
-
Jim Cramer on Medtronic (MDT): “I Think That Everything They’ve Been Doing Lately Is Right”
Yahoo! Finance: MDT News · 28 Mar 2026
-
Medtronic’s Stealth AXiS FDA Win Meets Mixed Share Performance
Yahoo! Finance: MDT News · 28 Mar 2026
-
GlucoTrack Stock Gains As Data Backs FDA Filing Plans For Glucose Monitoring Tech
benzinga · 27 Mar 2026
-
Medtronic Says Stealth AXiS Surgical System Receives FDA Clearance for Cranial, ENT Procedures
MT Newswires · 27 Mar 2026
Analist Konsensüsü
Fikir Birliği Derecelendirmesi
MDT için Benzinga, Yahoo Finance ve Finnhub'dan toplanan Al/Tut/Sat önerileri.
Fiyat Hedefleri
Konsensüs hedefi: $113.78
MoonshotScore
Bu puan ne anlama geliyor?
MoonshotScore, MDT'ın büyüme potansiyelini inovasyon, pazar yıkımı, finansal sağlık ve momentum dahil olmak üzere birden fazla faktörde 0-100 ölçeğinde derecelendirir.
Rakipler & Benzerleri
Son Haberler
Jim Cramer on Medtronic (MDT): “I Think That Everything They’ve Been Doing Lately Is Right”
Medtronic’s Stealth AXiS FDA Win Meets Mixed Share Performance
GlucoTrack Stock Gains As Data Backs FDA Filing Plans For Glucose Monitoring Tech
Medtronic Says Stealth AXiS Surgical System Receives FDA Clearance for Cranial, ENT Procedures
Medtronic plc Hissesi: Cevaplanan Temel Sorular
MDT için değerlendirilmesi gereken temel faktörler nelerdir?
Medtronic plc (MDT) şu anda yapay zeka skoru 56/100, orta puanı gösteriyor. Hisse 24.2x F/K oranıyla işlem görüyor, S&P 500 ortalamasına (~20-25x) yakın. Analist hedefi $113.78 ($87.14'dan +31%). Temel güçlü yan: Diversified product portfolio across multiple therapeutic areas.. İzlenmesi gereken birincil risk: Potential: Product liability claims and recalls.. Bu bir finansal tavsiye değildir.
MDT MoonshotScore'u nedir?
MDT şu anda MoonshotScore'da 56/100 (Derece C) alıyor, bu da orta derecelendirme gösteriyor. Puan, 9 kantitatif KPI genelinde büyüme potansiyelini, finansal sağlığı, piyasa momentumunu ve risk faktörlerini değerlendirir. En son piyasa verileri kullanılarak günlük olarak yeniden hesaplanır. Bu puan yalnızca bilgilendirme amaçlıdır.
MDT verileri ne sıklıkla güncellenir?
MDT fiyatları ABD piyasa saatleri (hafta içi 9:30-16:00 ET) sırasında gerçek zamanlı olarak güncellenir. Temeller, üç aylık veya yıllık beyanlardan sonra yenilenir. Analist derecelendirmeleri ve yapay zeka öngörüleri günlük olarak güncellenir. Haberler, finans kaynaklarından sürekli olarak toplanır.
Analistler MDT hakkında ne diyor?
Analistler, MDT için $113.78 konsensüs fiyat hedefi belirledi, bu mevcut fiyattan ($87.14) yukarı yönlü %31 potansiyeli temsil ediyor. Kapsam, al, tut ve sat derecelendirmelerini, kazanç tahminlerini ve son yükseltmeleri veya düşürmeleri içerir. Tüm ayrıntılar için bu sayfadaki Analist Konsensüsü bölümüne bakın.
MDT'a yatırım yapmanın riskleri nelerdir?
MDT için risk kategorileri arasında piyasa riski, şirkete özgü risk (yönetim, rekabet), finansal risk (borç, nakit yakımı) ve makroekonomik risk (oranlar, enflasyon) yer alır. Yapay zeka analizi tarafından belirlenen önemli bir risk: Potential: Product liability claims and recalls.. 1,0'ın üzerindeki beta, S&P 500'den daha yüksek volatiliteyi gösterir. Ayrıntılar için bu sayfadaki Risk Faktörleri bölümünü inceleyin. Tüm yatırımlar kayıp riski taşır.
MDT'ın P/E oranı nedir?
Medtronic plc (MDT)'nın son P/E oranı 24.2, ki bu da orta bir aralıkta. P/E (fiyat-kazanç) oranı, hisse senedi fiyatını hisse başına kazancıyla karşılaştırır. Bağlam için bunu sektördeki emsallerle ve S&P 500 ortalamasıyla (~20-25x) karşılaştırın. Yüksek bir P/E beklenen gelecekteki büyümeyi yansıtabilirken, düşük bir P/E değer düşüklüğünü veya azalan kazançları gösterebilir. Bu bir finansal tavsiye değildir.
MDT aşırı değerli mi, yoksa düşük değerli mi?
Medtronic plc (MDT)'ın aşırı değerli mi yoksa düşük değerli mi olduğunu belirlemek, birden fazla metriği incelemeyi gerektirir. P/E oranı 24.2. Analist hedefi $113.78 (mevcut fiyattan +31%), analistlerin yukarı yönlü potansiyel gördüğünü gösteriyor. Kapsamlı bir görünüm için değerleme oranlarını (P/E, P/S, EV/EBITDA) sektördeki emsallerle karşılaştırın. Bu bir finansal tavsiye değildir.
MDT'ın temettü verimi nedir?
Medtronic plc (MDT) şu anda düzenli bir temettü ödemiyor veya temettü verimi verileri mevcut değil. Büyüme odaklı şirketler genellikle temettü ödemek yerine karları yeniden yatırır. En son temettü bilgileri ve ödeme geçmişi için Finansallar sekmesini kontrol edin.
Sorumluluk reddi: Bu içerik yalnızca bilgilendirme amaçlıdır ve yatırım tavsiyesi teşkil etmez. Her zaman kendi araştırmanızı yapın ve bir finans uzmanına danışın.
Resmi Kaynaklar
Veriler yalnızca bilgilendirme amaçlı sağlanmıştır.
- Financial data may be subject to change.
- Stock data pending update.